Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$81.5MBeat by $877.8K
EPS-$0.13Beat by $0.05
Revenue estimate$80.6M
EPS estimate-$0.18

Next report

Oct 27, 2026 (in a month)
Revenue estimate$141.7M
EPS estimate$0.17

Financials

Q2 2025

Income statement

See full
Revenue$81.5M+164%
Gross profit$74.0M+170%
Operating income-$14.6M+70.8%
Net income-$15.9M+69.6%
EPS (diluted)-$0.13+69.0%

Balance sheet

See full
Cash & equivalents$73.0M-13.9%
Total debt$110.2M-46.9%
Total equity$139.0M-25.5%
Total assets$352.4M-20.8%

Cash flow

See full
CapEx$78.0K—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.71B+58.7%
Enterprise value$1.75B+45.5%
P/S6.5×-1.7×

Profitability

See full
Gross margin89.1%-3.2pp
Operating margin-32.6%-14.1pp
Net margin-35.4%-15.3pp

Returns & leverage

See full
Return on equity-57.3%-21.8pp
Debt / equity0.8×-0.3×
Current ratio3.2×-5.3×

Segments

By product

See full
ZORYVE Cream0.3$27.7M—
ZORYVE Cream0.15$14.6M—
ZORYVE Cream0.05-—

By segment

See full
Reportable Segment$81.5M+164%

FAQ

When did Arcutis Biotherapeutics, Inc. report Q2 2025 earnings?
Arcutis Biotherapeutics, Inc. (ARQT) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Arcutis Biotherapeutics, Inc.'s Q2 2025 revenue and EPS?
Arcutis Biotherapeutics, Inc. reported revenue of $81.5M and eps of $-0.13 for Q2 2025.
Did Arcutis Biotherapeutics, Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $80.6M by $877.8K. EPS beat the consensus estimate of $-0.18 by $0.05.
How did Arcutis Biotherapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 164.1% from $30.9M a year earlier and eps grew 69.0% from $-0.42.
Where can I find Arcutis Biotherapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001787306-25-000122) and the 10-Q periodic report (0001787306-25-000124) directly on SEC EDGAR. The filing index links above go to sec.gov.